Literature DB >> 382150

A double-blind crossover trial of domperidone in chronic postprandial dyspepsia.

W Englert, D Schlich.   

Abstract

A doubld-blind crossover study of oral domperidone (10 mg t.d.s.) involving 48 patients suffering from chronic postprandial dyspepsia, showed a significant relief of symptoms on active treatment compared to placebo. The trial lasted eight weeks, the crossover in medication taking place at four weeks. Side effects were rare and mild and it is concluded that domperidone could be a very useful drug for the symptomatic treatment of upper gastrointestinal distress.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 382150

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  5 in total

Review 1.  Domperidone, a new dopamine antagonist.

Authors:  M C Champion; M Hartnett; M Yen
Journal:  CMAJ       Date:  1986-09-01       Impact factor: 8.262

2.  On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.

Authors:  J Heykants; R Hendriks; W Meuldermans; M Michiels; H Scheygrond; H Reyntjens
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

3.  Approach to dyspepsia.

Authors:  T Koppert; T J Elmslie
Journal:  Can Fam Physician       Date:  1988-03       Impact factor: 3.275

Review 4.  Functional dyspepsia. Current treatment recommendations.

Authors:  Gerald Holtmann; Nicholas J Talley
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 5.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.